iBio has released preclinical data showing that its Activin E antibody IBIO-610, when combined with semaglutide, dramatically reduced skeletal muscle loss during weight reduction — a signal that could reshape how the functional nutrition and supplement industries approach GLP-1-adjacent product development.
In an eight-week obese non-human primate (NHP) study, lean mass accounted for just 6% of total weight lost in the IBIO-610-plus-semaglutide arm, compared with 22% in animals receiving semaglutide alone. The finding underscores a well-documented liability of GLP-1 receptor agonist therapy: while these drugs deliver significant fat loss, they also drive meaningful muscle catabolism — an outcome increasingly scrutinized by clinicians and, more recently, by the functional foods and sports-nutrition supply chain.
The Mechanism
Activin E is a member of the TGF-β superfamily of signaling proteins known to regulate muscle mass and adipose tissue metabolism. By blocking Activin E, IBIO-610 appears to shift the composition of weight lost away from lean tissue and toward fat mass. This myostatin-pathway-adjacent mechanism has attracted significant R&D attention as GLP-1 prescriptions have scaled: analysts tracking the weight-management category estimate that muscle-preservation co-therapies could represent a multi-billion-dollar adjacent market as semaglutide and tirzepatide use continues to expand across both prescription and consumer wellness channels.
For finished-formulation developers and ingredient suppliers, the NHP data point is notable even at this early stage. The functional nutrition sector has already seen a surge in high-protein, leucine-enriched, and HMB-containing products marketed to GLP-1 users seeking to preserve lean mass through dietary means. A validated pharmaceutical mechanism targeting Activin E could eventually inform companion supplement positioning — or, if IBIO-610 advances through IND and clinical phases, create a new class of co-therapy that operators in the medical-nutrition and clinical-channel space will need to understand.
Operator Implications
The GLP-1 weight-management wave has become one of the most disruptive forces in functional food and supplement category planning. Brands across protein nutrition and weight management segments are actively reformulating — boosting protein density, adding creatine, and incorporating branched-chain amino acids — specifically to address the muscle-loss side effect that NHP data like iBio's now quantifies with greater precision.
For trade buyers and product developers tracking the clinical pipeline, IBIO-610's non-human primate results establish a meaningful mechanistic benchmark: 22% lean-mass loss with semaglutide alone is a hard number that functional nutrition marketers can now reference when substantiating structure-function claims around muscle support in GLP-1 users. Whether or not IBIO-610 itself ever reaches a finished formulation, the Activin E target it validates will likely accelerate interest in botanical and peptide-based ingredient candidates that operate through overlapping myogenic pathways. The gut health and metabolic wellness category, already intersecting with GLP-1 discourse through microbiome and satiety research, may also find adjacent positioning opportunities as this science matures.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.